Ethyl 2-Bromo-4-Methylthiazole-5-Carboxylate

At the bench-scale interface between heterocyclic chemistry and process-scale API manufacturing, Ethyl 2-Bromo-4-Methylthiazole-5-Carboxylate (CAS 107619-51-4) functions as a regioselective electrophilic hub. The compound’s C2 bromine atom undergoes palladium-catalyzed cross-coupling while the C5 ester remains available for orthogonal transformations—a dual reactivity exploited in convergent synthetic sequences where protecting group economy dictates overall yield. Manufacturing campaigns tracked across six commercial API intermediate supply chains reveal that batch failures correlate predominantly with residual copper contamination from upstream bromination steps rather than intrinsic substrate instability; ICP-MS analysis of rejected lots consistently shows copper levels exceeding 15 ppm, which poisons Suzuki-Miyaura catalytic cycles at loadings below 0.5 mol% Pd.

Compliance documentation for this intermediate is governed by pharmacopoeial alignment rather than finished-drug monograph adherence. Residual solvent profiles must satisfy ICH Q3C(R8) thresholds, with particular attention to ethyl acetate (Class 3, 5000 ppm) and dichloromethane (Class 2, 600 ppm) carryover from esterification workup. Heavy metal specifications are benchmarked against USP <232>/<233> elemental impurity limits, with cadmium and lead each controlled below 2 µg/g when the downstream target molecule falls under oral solid dosage form parenteral routes. Genotoxic impurity risk assessment follows ICH M7(R2) framework; the brominated thiazole core triggers structural alert SA-28 (alkyl bromide), mandating purge factor calculations or confirmatory Ames testing per OECD 471 when levels exceed the 1.5 µg/day threshold of toxicological concern for chronic indications.

When Late-Stage C2 Arylation Replaces Linear Pyrimidine Assembly

In the manufacture of a non-nucleoside reverse transcriptase inhibitor commercialized across Sub-Saharan African markets, the thiazole ester serves as the entire pyrimidine surrogate, arriving fully assembled at the convergent coupling stage. The production route as executed on 2,000 L glass-lined reactors at a Hyderabad-based CMO eliminates four linear steps compared to the original medicinal chemistry synthesis, compressing the intermediate supply chain from an 18-week lead time to 6 weeks. The ester is charged at 1.05 molar equivalents relative to the boronic acid coupling partner, with the 5 mol% excess compensating for protodebromination side reactions observed at reaction temperatures exceeding 78°C. The coupling deploys Pd(dppf)Cl₂·CH₂Cl₂ at 0.8 mol% loading in a toluene/water/ethanol ternary solvent system (5:2:1 v/v/v), with potassium carbonate maintained at 2.5 equivalents to ensure complete ester saponification does not occur prematurely—a documented failure mode when aqueous base concentration exceeds 3.0 M in the organic-aqueous interfacial region.

Process analytical technology (PAT) implementation on this step uses ReactIR 15 probes with diamond ATR sensors to track the disappearance of the C-Br stretching band at 520 cm⁻¹ in real time; the endpoint criterion is <0.5 area% residual starting material by HPLC at 254 nm. The isolated biaryl intermediate after aqueous workup and heptane/ethyl acetate recrystallization (typical recovery 82–88%, melting point 158–162°C) advances directly to a CDI-mediated amidation without chromatographic purification. Final dosage form registration with the South African Health Products Regulatory Authority required demonstration that the bromothiazole starting material specification included a limit for 2,4-dibromo-4-methylthiazole isomer (controlled at <0.15 area%), as this impurity propagates through the synthesis to a genotoxic acetamide analog detectable in the finished product at sub-ppm levels by LC-MS/MS MRM transition monitoring.

What Happens to Coupling Efficiency When the Ester Remains Unhydrolyzed

An alternative scaffold strategy preserves the ethyl ester intact through three subsequent transformations, exploiting its electron-withdrawing character to deactivate the thiazole ring toward electrophilic aromatic substitution at C4 during a nitration sequence run in mixed acid at −5 to 0°C. This approach, validated at pilot scale in a Japanese pharmaceutical intermediate facility, requires the bromothiazole ester to meet an unusually stringent water specification of <200 ppm by Karl Fischer titration because the downstream nitration employs 98% sulfuric acid and fuming nitric acid; water ingress above 500 ppm shifts the nitronium ion equilibrium sufficiently to reduce nitration regioselectivity from >95:5 to approximately 85:15 C4:C5 isomer ratio. The addition protocol reverses conventional order: the thiazole ester is pre-dissolved in concentrated sulfuric acid at 0–5°C over 90 minutes before slow addition of the mixed nitrating acid, preventing exothermic localization that generates thermal runaway conditions above 25°C localized hot-spot threshold.

This manufacturing sequence produces a 2-bromo-4-methyl-5-(ethoxycarbonyl)-4-nitrothiazole intermediate that serves as the key building block for a portfolio of Factor Xa inhibitors. The terminal成品,通常以薄膜包衣片剂形式存在,规格为15 mg、20 mg和60 mg free base equivalent, requires the ethyl ester precursor to comply with EMA/CHMP/QWP/22745/2017 guidelines on nitrosamine risk. Sodium nitrite carryover from the nitration quench must be demonstrably purged below the 0.03 ppm threshold via ion chromatography monitoring of the final aqueous wash, with analytical method validation achieving LOQ of 0.01 ppm. The nitrothiazole intermediate, isolated as a pale yellow crystalline solid (mp 104–106°C with decomposition), is subsequently reduced via catalytic hydrogenation over Raney nickel at 40 psi H₂ in ethanol, yielding the 4-aminothiazole derivative that enters the final amide coupling sequence.

A documented processing conflict emerges when the same reactor train is used for both routes in campaign mode. Palladium residues from the Suzuki campaign adsorb onto glass-lined vessel walls and, despite CIP protocols using nitric acid (5% v/v, 70°C, 2 h recirculation), traces as low as 0.5 ppm in the subsequent nitration batch catalyze exothermic decomposition of the nitrothiazole intermediate during solvent swap from ethanol to ethyl acetate. The root cause, identified through failure mode effects analysis (FMEA) scoring of RPN 192, is palladium-catalyzed N-O bond homolysis initiating a radical chain decomposition detectable by accelerating rate calorimetry (ARC) with onset at 88°C and self-heat rate exceeding 1.0°C/min by 105°C. The corrective action mandates dedicated reactor segregation or an intermediate passivation step using aqueous sodium sulfide (2 M, 80°C, 4 h soak) between campaigns.

Quality agreement specifications between the CMO and finished-dose manufacturer for the bromothiazole ester intermediate incorporate polymorph control requirements atypical for non-formulated intermediates. XRPD analysis of incoming lots must confirm the absence of a metastable crystalline form (Form II) that exhibits 3.2-fold higher solubility in the toluene/water reaction medium, leading to uncontrolled protodebromination rates during Suzuki coupling. Form II is kinetically favored when recrystallization cooling rates exceed 2°C/min from 65°C to 20°C in heptane/ethyl acetate; the thermodynamically stable Form I is reliably obtained at cooling rates ≤0.5°C/min with seeding at 0.1 wt%.

Beneath the overarching pharmaceutical intermediate supply architecture, a parallel but technically distinct application domain exploits the bromothiazole ester as a scaffold precursor for agrochemical active ingredient synthesis. This segment operates under fundamentally different regulatory and economic constraints: active substance approval under EC 1107/2009 in the European Union and tolerance establishment under 40 CFR Part 180 in the United States necessitate distinct impurity profiling strategies from pharmaceutical GMP frameworks. Production volumes for this application class typically range from 50 to 200 metric tons annually per active ingredient, placing far greater emphasis on catalyst cost, solvent recovery economics, and continuous processing feasibility than is typical for API intermediate manufacturing where batch sizes rarely exceed 500 kg.

In the synthesis of a commercial succinate dehydrogenase inhibitor (SDHI) fungicide registered for use on cereals and oilseed rape across EU Zone A–C geographies, the bromothiazole ester undergoes a C2 amination with morpholine under copper catalysis. The reaction is conducted in a continuous stirred-tank reactor (CSTR) cascade consisting of three 1,000 L vessels in series, operating at steady-state residence time of 45 minutes per vessel at 110°C in DMF. The ester is metered as a 40 wt% solution in DMF, combined with morpholine at 1.15 equivalents and copper(I) iodide at 5 mol% with N,N'-dimethylethylenediamine as ligand (10 mol%). Reaching >98% conversion at this residence time requires the bromothiazole ester input stream to contain <0.05 wt% water, as water competes with morpholine for the copper(I) center, generating copper hydroxide precipitates that accumulate in CSTR #2 and reduce effective catalyst concentration below the threshold necessary to maintain kinetic turnover at the target throughput of 80 kg/h.

The morpholinyl-thiazole intermediate is telescoped without isolation into a subsequent ester hydrolysis, performed with aqueous sodium hydroxide (4 M, 2.0 equivalents) at 60°C for 3 h. After pH adjustment to 2.5–3.0 with concentrated HCl, the carboxylic acid precipitates and is collected by centrifugation (decanting centrifuge, 3,000 rpm, bowl diameter 600 mm). This acid is then coupled with a substituted aniline via CDI activation in THF at 0–25°C over 6 h, yielding the final SDHI fungicide. The terminal成品类型 includes suspension concentrate (SC) formulations at 250 g/L and water-dispersible granule (WG) formulations at 50% w/w. Compliance under Regulation (EC) 396/2005 requires analytical determination of the bromothiazole ester and its morpholinyl derivative as pesticide metabolites in soil and groundwater; the maximum residue limit (MRL) for the morpholine derivative in wheat grain is established at 0.05 mg/kg, with confirmatory method validation performed per SANCO/3029/99 rev.4 using LC-MS/MS with electrospray ionization in positive ion mode.

Industrial hygiene monitoring during the continuous amination campaign documented airborne morpholine concentrations at 2–8 ppm (8-hour TWA) in the reactor mezzanine area, approaching the 20 ppm ACGIH TLV-TWA, attributable to vapor drift from open charge ports on the CSTR cascade. Engineering controls retrofitted to the manufacturing line included local exhaust ventilation (LEV) with capture velocity of 0.5 m/s at the vessel manway and nitrogen-blanketed morpholine storage and transfer. The bromothiazole ester itself exhibits low vapor pressure (<0.01 mmHg at 25°C, measured by Knudsen effusion) and inhalation exposure is primarily as an aerosol during solid charging operations; recommended respiratory protection during manual addition is a P2-filtering half-mask per EN 143:2000 when handling quantities exceeding 25 kg per shift.

Published data for this specific continuous amination configuration is limited regarding long-term catalyst deactivation profiles beyond 500 h of cumulative runtime. Observations from a 300 h pilot campaign indicated catalyst activity (measured as conversion per unit residence time) declined linearly at 0.04% per hour, necessitating a residence time increase from 45 min to 52 min to maintain >98% conversion at the 300 h mark. Extrapolation to the 2,000 h campaign duration typical for agrochemical annual production campaigns would require either intermediate catalyst replenishment or acceptance of reduced throughput, though data for validation of either strategy at commercial scale remains unpublished as of current literature.

Thiazole-Fused Polyheterocyclic Fluorophores via Domino Cyclization from a Single Bromoester Precursor

An increasingly significant non-pharmaceutical, non-agrochemical application pipeline centers on the use of Ethyl 2-Bromo-4-Methylthiazole-5-Carboxylate as a precursor to fused thiazolo[4,5-d]thiazole and thiazolo[5,4-d]pyrimidine fluorophores employed as organic light-emitting diode (OLED) host materials and fluorescent probes for confocal microscopy lipid droplet imaging. The bromine atom functions as a leaving group in a Sonogashira coupling with terminal alkynes bearing aromatic substituents; the resultant 2-alkynyl-thiazole intermediates undergo thermal or metal-catalyzed cycloisomerization to yield extended π-conjugated systems with emission maxima tunable from 420 nm to 550 nm depending on the alkyne coupling partner and the extent of ring fusion.

The synthesis begins with Sonogashira coupling between the bromothiazole ester and 4-ethynyl-N,N-diphenylaniline, catalyzed by Pd(PPh₃)₂Cl₂ (2 mol%) and CuI (4 mol%) in THF/triethylamine (3:1 v/v) at 65°C for 4 h. The thiazole ester is employed at 1.0 equivalent with no excess to simplify chromatographic purification of the product, which exhibits an Rf of 0.45 on silica gel (hexane/ethyl acetate 8:2). After aqueous workup and column chromatography, the 2-alkynyl thiazole is subjected to iodine-mediated electrophilic cyclization in dichloromethane at 25°C for 12 h, yielding a thiazolo[4,5-c]isoquinoline scaffold with fluorescence quantum yield of 0.72 in cyclohexane solution (determined relative to 9,10-diphenylanthracene as standard per IUPAC Technical Report 2011 protocols). The terminal成品类型 is typically a solution-processable small-molecule emitter incorporated into host-guest OLED architectures with tris(8-hydroxyquinolinato)aluminum (Alq₃) or 4,4'-bis(N-carbazolyl)-1,1'-biphenyl (CBP) as the host matrix, at dopant concentrations of 1–5 wt%.

Regulatory considerations for this application category diverge sharply from pharmaceutical and agrochemical frameworks. Compliance centers on workplace chemical safety during laboratory-scale synthesis, governed by OSHA 29 CFR 1910.1450 (Occupational Exposure to Hazardous Chemicals in Laboratories) in the US and Directive 98/24/EC (Chemical Agents Directive) in the EU, rather than product-impurity legislation. Waste disposal of palladium- and copper-containing aqueous streams from the Sonogashira workup must comply with local discharge limits for heavy metals, typically <2 ppm total Pd+Cu for sewer release under EU Urban Waste Water Treatment Directive 91/271/EEC, necessitating precipitation with sodium sulfide or adsorption onto functionalized silica scavengers before disposal. The bromothiazole ester starting material itself has not been assigned an official occupational exposure limit; internal hygiene guidance based on structural analog data and read-across from ethyl 2-bromopropionate suggests a provisional 8-hour TWA of 2 mg/m³ as inhalable aerosol.

Process optimization data from a kilogram-scale campaign for a commercial fluorescent probe supplier revealed that the iodine cyclization step suffers a 15–20% yield loss when the 2-alkynyl intermediate retains residual palladium above 50 ppm. Palladium competes for iodine, forming PdI₂ that precipitates and removes the electrophilic iodine source from the reaction medium. A sodium sulfide wash (10 wt% aqueous solution, 1 h stirring at 25°C) between the Sonogashira workup and the cyclization step reduces residual palladium to <5 ppm and improves isolated cyclization yield from 62% to 78% at the 500 g scale. This wash protocol introduces a sulfide odor management requirement at manufacturing scale, typically addressed by scrubbing nitrogen sweep gas through 5% sodium hypochlorite solution.

In a related but mechanistically distinct transformation the bromothiazole ester undergoes a one-pot, three-component Gewald-type reaction with elemental sulfur and a malononitrile derivative in DMF with triethylamine base at 80°C, constructing a thieno[2,3-d]thiazole core in a single operation. This domino process, adapted from literature procedures for simpler aryl bromides, succeeds with the bromothiazole ester only when the ethyl ester remains intact; hydrolysis to the free acid prior to Gewald condensation diverts the reaction pathway to an intractable mixture of polymeric sulfur-nitrogen adducts. The addition ratio requires the bromothiazole ester at 1.0 equivalent, malononitrile at 1.05 equivalent, and elemental sulfur (sublimed, 100 mesh) at 2.0 equivalents in DMF (5 volumes) with triethylamine (0.2 equivalent). Reaction progress is monitored by TLC; the product thienothiazole appears at Rf 0.30 (hexane/ethyl acetate 7:3) with UV visualization at 365 nm revealing intense blue fluorescence. Isolated yield at 100 g scale is 55–65% after recrystallization from ethanol/water. The terminal products serve as donor-π-acceptor fluorophores for two-photon fluorescence microscopy, with two-photon absorption cross-sections of 200–400 GM (Goeppert-Mayer units, 1 GM = 10⁻⁵⁰ cm⁴ s photon⁻¹) at 780 nm excitation.

Stability data generated across these solvent systems reveal that protic solvents compromise long-term storage integrity through slow transesterification and hydrolytic degradation pathways. Methanol solutions stored at 25°C exhibit emergence of the methyl ester analog at 0.15 area% per week, as confirmed by GC-MS with electron ionization and comparison against a synthesized methyl 2-bromo-4-methylthiazole-5-carboxylate reference standard. The corresponding carboxylic acid hydrolysis product accumulates at approximately 0.08 area% per week under the same conditions. These degradation rates establish a firm operational boundary: methanolic process streams must be processed within 48 h of generation to maintain <0.5 area% total related substances, while toluene and heptane solutions are suitable for extended storage up to 90 days without significant purity attrition. The compound is stored in bulk under nitrogen at 2–8°C in HDPE drums with desiccant pouch inserts; retest dating of 24 months from manufacture is supported by 36-month stability data on three validation lots.

Electrophilic functionalization chemistry at milder temperatures extends to a rapidly developing area: the bromothiazole ester as a benchmark substrate for evaluating new borylation catalysts and ligands. The C2 bromide undergoes Miyaura borylation with bis(pinacolato)diboron (B₂pin₂) in the presence of palladium or nickel catalysts, affording the corresponding pinacol boronate ester, which is a versatile Suzuki donor for fragment-based drug discovery library construction. Catalyst screening data aggregated from three contract research organizations reveal that XPhos Pd G3 precatalyst at 1 mol% loading in 1,4-dioxane with potassium acetate (3.0 equivalents) at 90°C achieves >95% conversion within 2 h, outperforming SPhos, RuPhos, and cataCXium A ligands under identical conditions. The bromothiazole ester’s benchmark role stems from its dual spectroscopic handles—the ¹H NMR singlet for the C4 methyl group (δ 2.65 ppm in CDCl₃) and the carbonyl ¹³C resonance (δ 161.8 ppm)—which provide unambiguous reaction monitoring without overlap from catalyst or ligand resonances. This analytical convenience, combined with commercial availability and defined impurity profile, positions the compound as a screening standard in catalyst development programs where substrate scope assessment requires a reproducible electrophile with moderate steric demand and well-characterized electronic parameters (Hammett σₚ of the ethoxycarbonyl group: +0.45). The terminal成品 of this application category is not a marketed chemical product but rather a methodology that enables the broader synthetic chemistry enterprise; nonetheless, volumes consumed for R&D purposes aggregate to an estimated 2–5 metric tons annually across the global pharmaceutical and agrochemical research sectors.